foto
LATEST NEWS

 OctoPlus announces 2010 first half-year results



WEBCAST HALF-YEAR RESULTS

Click here to access the webcast of 6 August 2010



OCTOPLUS OPENED NYSE EURONEXT

In celebration of OctoPlus' 15 year anniversday, CEO Simon Sturge and CFO Susan Swarte opened the financial markets in Amsterdam on Tuesday 27 July



OCTOPLUS ANNUAL REPORT 2009
VIEW OUR WEB SEMINARS
OCTO SHARE PRICE
HOME dashNL dash CONTACT

 

JAPANESE ENCEPHALITIS VACCINE

OctoPlus works together with SingVax , a Singapore-based vaccine development company, to co-develop a single-shot Japanese encephalitis (JE) vaccine.

Single-shot vaccine innovation
Existing JE vaccines typically require two or three doses. By creating a single-shot JE vaccine we aim to achieve increased patient compliance and greater efficacy of the vaccine. As such, it will help protect more people from this life threatening disease.

Significant market potential
We target a significant proportion of the estimated US$400 million global market for JE vaccines. To date, no single-shot JE vaccine exists that is available on an international scale.

What is Japanese encephalitis?
The JE virus causes an encephalopathy, a fever of the brain that can lead to death or severe neurological damage in survivors. According to the WHO, approximately 50,000 cases are reported in Asia annually, with approximately 15,000 deaths attributed directly to infection with JEV.